20629-35-0

Basic information

• Product Name: (E)-4-bromobut-2-enoic acid
• Synonyms: (E)-4-bromobut-2-enoic acid
• CAS NO: 20629-35-0
• Molecular Formula: C₄H₅BrO₂
• Molecular Weight: 164.99
• Mol File: 20629-35-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 73-74 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 287.6±23.0 °C(Predicted)
• Appearance: /
• Density: 1.718±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.13±0.10(Predicted)
• CAS DataBase Reference: (E)-4-bromobut-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-bromobut-2-enoic acid(20629-35-0)
• EPA Substance Registry System: (E)-4-bromobut-2-enoic acid(20629-35-0)

Safety Data

• Hazardous Substances Data: 20629-35-0(Hazardous Substances Data)

Usage

Description

(E)-4-bromobut-2-enoic acid, also known as 4-bromo-2-butenoic acid, is a chemical compound with the molecular formula C4H5BrO2. It is a colorless to light yellow liquid that is used as an intermediate in organic synthesis.

Uses

Used in Pharmaceutical Industry:
(E)-4-bromobut-2-enoic acid is used as a building block for the synthesis of various pharmaceuticals. It is utilized in the production of drugs due to its unique chemical properties and reactivity.
Used in Agrochemical Industry:
(E)-4-bromobut-2-enoic acid is used as an intermediate in the synthesis of agrochemicals. It contributes to the development of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Synthesis:
(E)-4-bromobut-2-enoic acid is used as a building block in the synthesis of various other organic compounds. Its reactivity and functional groups make it a valuable component in creating a wide range of organic molecules for different applications.
Safety Note:
(E)-4-bromobut-2-enoic acid is considered to be a hazardous substance and should be handled with caution due to its potential to cause irritation to the skin, eyes, and respiratory system. Proper safety measures and handling procedures should be followed to minimize risks during its use in various industries.

Upstream product

• 107-93-7 (E)-but-2-enoic acid 
• 1117-71-1 methyl-4-bromo-2-butenoate 
• 1117-71-1 methyl 4-bromocrotonate 
• 3724-65-0 2-butenoic acid 

Downstream Products

• 98548-81-3 trans-4-dimethylaminocrotonic acid hydrochloride 
• 69637-13-4 2-(1-hydroxy-1-phenylmethyl)but-3-enoic acid 
• 69637-13-4 2-(1-hydroxy-1-phenylmethyl)but-3-enoic acid 
• 1363359-87-8 (E)-N-(4-(3-chloro-4-fluorophenylamino)-7-((7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy)quinazolin-6-yl)-4-bromo-2-butenamide 
• 63968-74-1 (E)-4-methoxybut-2-enoic acid 
• 98548-82-4 4-(dimethylamino)but-2-enoic acid 
• 1144561-14-7 (E)-N-3-(6-[3-methylphenyl]aminopyrimidin-4-yl)aminophenyl-4-bromo-2-butenamide 
• 1144561-48-7 (E)-N-3-(6-[3-chloro-4-fluorophenylamino]pyrimidin-4-yl)aminophenyl-4-bromo-2-butenamide 

Relevant articles and documents

A steps Hua Tini chemical synthesis method (by machine translation)

The present invention provides a convenient steps Hua Tini chemical synthesis method, using the synthesis method adopted in the process of preparing steps Hua Tini cheap raw materials, is easy to obtain, and saves the production cost, and the adoption of the synthesis method of the high yield of the product, the whole in the preparation process of mild reaction conditions, the atom economy is high. (by machine translation)

NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Substituted 3-cyanoquinolines

This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.